bsm-52024R-BF594 [Conjugated Primary Antibody]
Bcl-XL Recombinant Antibody, AbBy Fluor® 594 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Bcl-XL

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 598

Swiss Prot: Q07817

Source: Recombinant human Bcl-XL protein, around 1-100aa.

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The protein encoded by this gene belongs to the BCL-2 protein family. BCL-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. The proteins encoded by this gene are located at the outer mitochondrial membrane, and have been shown to regulate outer mitochondrial membrane channel (VDAC) opening. VDAC regulates mitochondrial membrane potential, and thus controls the production of reactive oxygen species and release of cytochrome C by mitochondria, both of which are the potent inducers of cell apoptosis. Two alternatively spliced transcript variants, which encode distinct isoforms, have been reported. The longer isoform acts as an apoptotic inhibitor and the shorter form acts as an apoptotic activator. [provided by RefSeq, Jul 2008].

Conjugation: AbBy Fluor® 594

Excitation/ Emission: 590nm/617nm

Size: 100ul

Concentration: Lot dependent

Applications: WB(1:300-5000)
IF(ICC)(1:50-200)

Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Shuli Yang. et al. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from Juglans mandshurica Maxim. MOLECULES. 2024 Jan;29(9):1976Read more>>
  • ang-Hua Zhong. et al. Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2. ONCOL REP. 2024 Jul;52(1):1-13Read more>>
VALIDATION IMAGES